Article (Scientific journals)
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Hofland, Leo J; van der Hoek, Joost; van Koetsveld, Peter M et al.
2004In Journal of Clinical Endocrinology and Metabolism, 89 (4), p. 1577-1585
Peer Reviewed verified by ORBi
 

Files


Full Text
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro..pdf
Publisher postprint (1.44 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adenoma/secretion; Adult; Dose-Response Relationship, Drug; Female; Hormone Antagonists/administration & dosage/pharmacology; Human Growth Hormone/antagonists & inhibitors/secretion; Humans; Male; Middle Aged; Octreotide/administration & dosage/pharmacology; Pituitary Neoplasms/secretion; Prolactin/antagonists & inhibitors/secretion; Protein Isoforms/genetics; RNA, Messenger/metabolism; Receptors, Somatostatin/genetics; Somatostatin/administration & dosage/analogs & derivatives/pharmacology; Tumor Cells, Cultured
Abstract :
[en] To determine the inhibitory profile of the novel somatostatin (SRIF) analog SOM230 with broad SRIF receptor binding, we compared the in vitro effects of SOM230, octreotide (OCT), and SRIF-14 on hormone release by cultures of different types of secreting pituitary adenomas. OCT (10 nM) significantly inhibited GH release in seven of nine GH-secreting pituitary adenoma cultures (range, -26 to -73%), SOM230 (10 nM) in eight of nine cultures (range, -22 to -68%), and SRIF-14 (10 nM) in six of six cultures (range, -30 to -75%). The sst analysis showed predominant but variable levels of somatostatin receptor (sst)(2) and sst(5) mRNA expression. In one culture completely resistant to OCT, SOM230 and SRIF-14 significantly inhibited GH release in a dose-dependent manner with an IC(50) value in the low nanomolar range. In the other cultures, SOM230 showed a lower potency of GH release inhibition (IC(50), 0.5 nM), compared with OCT (IC(50), 0.02 nM) and SRIF-14 (IC(50), 0.02 nM). A positive correlation was found between sst(2) but not sst(5) mRNA levels in the adenoma cells and the inhibitory potency of OCT on GH release in vivo and in vitro, and the effects of SOM230 and SRIF-14 in vitro. In three prolactinoma cultures, 10 nM OCT weakly inhibited prolactin (PRL) release in only one (-28%), whereas 10 nM SOM230 significantly inhibited PRL release in three of three cultures (-23, -51, and -64.0%). The inhibition of PRL release by SOM230 was related to the expression level of sst(5) but not sst(2) mRNA. Several conclusions were reached. First, SOM230 has a broad profile of inhibition of tumoral pituitary hormone release in the low nanomolar range, probably mediated via both sst(2) and sst(5) receptors. The higher number of responders of GH-secreting pituitary adenoma cultures to SOM230, compared with OCT, suggest that SOM230 has the potency to increase the number of acromegalic patients which can be biochemically controlled. Second, compared with OCT, SOM230 is more potent in inhibiting PRL release by mixed GH/PRL-secreting adenoma and prolactinoma cells.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Hofland, Leo J
van der Hoek, Joost
van Koetsveld, Peter M
de Herder, Wouter W
Waaijers, Marlijn
Sprij-Mooij, Diana
Bruns, Christian
Weckbecker, Gisbert
Feelders, Richard
van der Lely, Aart-Jan
Beckers, Albert ;  Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Lamberts, Steven WJ
Language :
English
Title :
The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro.
Publication date :
April 2004
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Volume :
89
Issue :
4
Pages :
1577-1585
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 18 March 2010

Statistics


Number of views
145 (4 by ULiège)
Number of downloads
284 (3 by ULiège)

Scopus citations®
 
171
Scopus citations®
without self-citations
131
OpenCitations
 
138

Bibliography


Similar publications



Contact ORBi